Compare Dyne Therapeutics Inc. Common Stock (DYN) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs National Beverage Corp. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while National Beverage Corp. trades at $33.54 (market cap $3.14B). The key difference: Dyne Therapeutics Inc. Common Stock and National Beverage Corp. are close in size by market cap, and National Beverage Corp. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and National Beverage Corp. for 32 Days on average.
| DYN | FIZZ | |
|---|---|---|
Market Cap | $2.81B | $3.14B |
Volume | 2,195,902 | 359,096 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $37.73 |
52-Week Low | $14.60 | $29.20 |
Typical Hold Time | 0 Days | 32 Days |
Enterprise Value | $2.13B | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
National Beverage Corp. (FIZZ) trades at $32.99, up 2.61% today, with a bullish technical signal from moving averages despite recent earnings misses. The company maintains strong profitability with 36.21% gross margins and 40.13% ROE, though revenue growth has stalled at $1.2B annually. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026 but with margin pressure from input costs.
FIZZ faces mixed sentiment with 50% analyst sell ratings against bullish technical indicators. The stock offers strong profitability metrics but faces growth challenges and margin compression risks from tariffs and rising costs. Institutional buying continues despite earnings volatility, suggesting long-term confidence in the business model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
